THE WHAT? Beiersdorf is celebrating a ‘successful’ performance for fiscal 2021, reporting group sales increase of 9.7 percent to €7.6 billion, an improvement on 2019 figures.
THE DETAILS The manufacturer of Nivea said that thanks to large investments in the areas of sustainability, innovation and digitalization, both its Consumer Business Segment and tesa Business Segment upped market share and tapped new markets.
The Consumer Business Segment saw sales rise 8/8 percent to €6.1 billion thanks to a 32 percent rise in e-commerce business. The Consumer Business Segment now generates more than 10 percent of its sales online, Beiersdorf said. Core brand Nivea recorded organic sales growth of 5.5 percent while La Prairie saw demand increase 20.1 percent, driven by a recovery in the travel retail business. Revenue from the German cosmetics firm’s Derma brands Eucerin and Aquaphor rose strongly too (+19.5 percent).
On Group level, the operating result (EBIT) rose to €993 million and consolidated EBIT margin excluding special factors increased by 13 percent.
THE WHY? Vincent Warnery, CEO of Beiersdorf, explains, “2021 was not only a financially successful fiscal year for Beiersdorf, but also a year in which we took highly promising strategic steps to lay the groundwork for our future. We made very good progress in all areas of our C.A.R.E.+ strategy. We tapped new and attractive growth potential, enhanced our capacity to innovate, and achieved major milestones as part of our digital and sustainable transformation – despite many adverse circumstances resulting particularly from the coronavirus pandemic and higher material and transport costs.”
Aesthetic injectable companies refer to businesses or companies that specialize in manufacturing, distributing, or providing aesthetic injectable products and services. These companies focus on developing and supplying injectable substances used for cosmetic purposes, typically administered by qualified medical professionals. Aesthetic injectable companies play a crucial role in the field of aesthetic medicine and cosmetic dermatology by offering a variety of injectable products designed to enhance facial features, reduce wrinkles, and improve overall skin appearance.
Key aspects of aesthetic injectable companies include:
-
Product Development: These companies research, develop, and manufacture aesthetic injectables such as dermal fillers, botulinum toxins (e.g., Botox), collagen stimulators, and other specialized formulations. They often innovate new products to meet evolving market demands and technological advancements.
-
Distribution and Sales: Aesthetic injectable companies distribute their products through authorized channels, including healthcare providers, medical spas, and aesthetic clinics. They may also sell directly to licensed professionals who administer these treatments.
-
Regulatory Compliance: Due to the medical nature of their products, aesthetic injectable companies adhere to strict regulatory guidelines and obtain necessary approvals from health authorities (e.g., FDA in the United States) to ensure safety, efficacy, and quality standards.
-
Training and Support: Many companies provide training and educational support to healthcare professionals on the proper use, administration techniques, and safety protocols associated with their injectable products. This ensures that practitioners can deliver treatments effectively and safely.
-
Customer Support: Aesthetic injectable companies offer customer support services to healthcare providers and consumers, addressing inquiries, providing product information, and assisting with product usage and troubleshooting.
